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RESEARCH ARTICLE

Evolution of Multiple Domains of the HIV-1 Envelope
Glycoprotein during Coreceptor Switch with CCR5 Antagonist
Therapy
Yueqi Du,a Ellen Wu,a* Xiang Gao,a Jie Zhang,a§ John C. Martin,b Bruce A. Rosa,b Makedonka Mitreva,b,c

Lee Ratnera

Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA

a

Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA

b
c

McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri, USA

HIV-1 uses CD4 as a receptor and chemokine receptors CCR5 and/or
CXCR4 as coreceptors. CCR5 antagonists are a class of antiretrovirals used to inhibit
viral entry. Phenotypic prediction algorithms such as Geno2Pheno are used to assess
CCR5 antagonist eligibility, for which the V3 region is screened. However, there exist
scenarios where the algorithm cannot give an accurate prediction of tropism. The
current study examined coreceptor shift of HIV-1 from CCR5-tropic strains to CXCR4tropic or dual-tropic strains among ﬁve subjects in a clinical trial of the CCR5 antagonist vicriviroc. Envelope gene amplicon libraries were constructed and subjected to
next-generation sequencing, as well as single-clone sequencing and functional analyses. Approximately half of the ampliﬁed full-length single envelope-encoding clones
had no signiﬁcant activity for infection of cells expressing high levels of CD4 and
CCR5 or CXCR4. Functional analysis of 9 to 21 individual infectious clones at baseline
and at the time of VF were used to construct phylogenetic trees and sequence alignments. These studies conﬁrmed that speciﬁc residues and the overall charge of the
V3 loop were the major determinants of coreceptor use, in addition to speciﬁc residues in other domains of the envelope protein in V1/V2, V4, C3, and C4 domains
that may be important for coreceptor shift. These results provide greater insight into
the viral genetic determinants of coreceptor shift.
IMPORTANCE This study is novel in combining single-genome sequence analysis and
next-generation sequencing to characterize HIV-1 quasispecies. The work highlights
the importance of mutants present at frequencies of 1% or less in development of
drug resistance. This study highlights a critical role of speciﬁc amino acid substitutions outside V3 that contribute to coreceptor shift as well as important roles of the
V1/V2, V4, C3, and C4 domain residues.
KEYWORDS HIV, Envelope, CCR5, CXCR4, Coreceptor, CD4, Vicriviroc, HIV

H

IV-1 is the cause of a global infection of more than 75 million individuals over the
last 4 decades (1). Effective vaccines and curative therapies remain to be developed
(2, 3). One of the major challenges in prevention and treatment efforts is the high rate of
genetic divergence of HIV-1 strains (4). This results from the error-prone nature of the
reverse transcriptase, with 0.2 errors per genome during each replication cycle (5).
Additional errors occur during transcription by RNA polymerase II. In addition, HIV-1 replication is dynamic, with a viral generation time of 2.5 days with 1,010 to 1,012 new virions produced each day in an infected individual (6). Frequent recombination and natural
selection further enhance the rate of evolutionary change (7). This has resulted in multiple different clades of HIV-1 associated with different geographic areas (4). The persistent
nature of HIV infection results in evolution both within and among hosts (8).
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One of the most striking ﬁndings about HIV-1 genetic diversity is the extensive variation in the envelope gene (env), particularly sequences encoding the hypervariable
domains (V1 to V5) (9). The viral envelope is a trimeric complex of the 120-kDa surface
glycoprotein (SU, gp120), noncovalently associated with the gp41 transmembrane protein (TM) (10). The envelope protein mediates virus binding and entry (11). Therefore, it
is the major target of neutralizing antibodies (12). Virus entry is initiated by SU binding
to the primary receptor, CD4 (11). This leads to a conformational change, with alterations
in the V1/V2 loops allowing exposure of the V3 loop, which binds to cellular coreceptors
(13–15). The principal coreceptors for HIV-1 are C-C chemokine receptor 5 (CCR5) and
C-X-C chemokine receptor 4 (CXCR4) (13). Most infections of patients occur with HIV-1
strains that utilize CCR5, which are termed R5-tropic strains (16, 17). However, over time,
sequence changes in the envelope protein occur that allow the use of CXCR4 (18). These
strains are designated X4-tropic if they utilize CXCR4 and not CCR5, or dual- or R5X4-tropic
if they can utilize either coreceptor (19). After coreceptor binding, additional conformational
changes occur that open the trimeric envelope complex and lead to a conformational
change in the TM protein, which inserts into the host membrane and promotes viruscell membrane fusion (20).
The emergence of HIV-1 drug resistance remains one of the greatest challenges in
treatment (8). Latent HIV-1 reservoirs in patients on highly active antiretroviral therapy
serve to replenish the pool of replicating virus from a variety of CD41 cell types in tissues throughout the body (21). In addition to the approved reverse transcriptase, integrase, and protease inhibitors, there has been considerable effort to develop therapies
that block HIV-1 entry (22). Maraviroc (MVC) was developed as an inhibitor of envelope
binding to CCR5 (23). However, its speciﬁcity for CCR5, rather than CXCR4, restricted its
use to individuals with only R5-tropic virus. Although several genotypic algorithms
were developed, such as the Gene2Pheno prediction tool, they were not sufﬁciently
accurate for clinical use (24). Thus, phenotypic assays, such as the Troﬁle assay, are
required to accurately identify coreceptor use (25). Other inhibitors of HIV-1 entry have
been developed to block CD4 binding or TM conformational changes, but these drugs
require parenteral administration or are restricted to use for individuals that have failed
multiple other treatment regimens (22, 26, 27).
The current work examines isolates obtained from subjects on a trial of an alternate
CCR5 antagonist, vicriviroc (VCV) (28). Although VCV has similar activity to MVC, the
pharmaceutical producer chose not to continue its therapeutic development (29).
The inhibitory spectrum of VCV appears very similar to that of MVC (30, 31). Thus, we
further analyzed the samples from a phase II clinical trial of vicriviroc, derived from the
subset of individuals who developed virological failure (VF) and a shift from CCR5 to
CXCR4 use while on treatment (28).
Eligibility for this trial was based on the presence in the plasma of exclusively R5 virus,
as determined by the Troﬁle tropism assay, and VF while receiving a ritonavir-containing
regimen, with a plasma HIV-1 level of at least 5,000 copies/mL. Eight subjects who experienced protocol-deﬁned VF were selected out of a total of nine subjects with VF and
change in coreceptor use from the entire population of 106 protocol subjects (28).
Samples were obtained at two time points: study baseline (time point 1) and VF
(time point 2) (32). The amount of time between time points 1 and 2 varied between
subjects, ranging from 2 to 32 weeks. env sequence libraries were generated under limiting dilution conditions for each subject (33) and cloned into the pNL4-3Env-Luc1
plasmid containing an infectious molecular clone of HIV-1 lacking the env gene, with
the ﬁreﬂy luciferase gene in place of the nef gene. Illumina sequences were generated
for each amplicon library. A clustering analysis using single-nucleotide polymorphism
(SNP) information of the 16 amplicon libraries was performed (34, 35). Analysis of the
V3 coding sequence showed that there was a similar degree of heterogeneity in each
library (33). Moreover, the clustering pattern demonstrated that V3 sequences from
the two time points for each subject were more similar to one another than to those of
other subjects, in agreement with a previous study (33, 36).
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RESULTS
Panel of recombinant env clones. Samples from subjects 1, 3, 4, 6, 7, and 8, which
shifted primarily to X4-using clones after VCV treatment, were utilized in the current
study. Individual molecular clones from time points 1 and 2 of subjects 1, 4, 6, 7, and 8
were isolated, sequenced, and characterized for coreceptor use. An insufﬁcient number
of clones from subject 3 were obtained for these analyses, and subject 3 was excluded
from the study. Analysis of V3 sequences by the Geno2Pheno algorithm conﬁrmed
that the majority of clones switched from R5-tropic to X4-using after treatment with
VCV. The exception was subject 7, from whom 9.0% of baseline clones were predicted
to be X4-using clones. Results of NGS analysis of the V3 sequences in the amplicon
libraries are shown in Fig. 1. Below each pie graph are shown the number of reads
obtained with full-length V3 domain sequences. The slice of each pie denotes the proportion of each sequence variant found within the library, with identical colors used to
indicate identical V3 sequences. The most predominant clone at baseline accounted
for 33.7 to 81.2% of sequences. For subjects 1 and 4, a single predominant clone was
found, but for subjects 6 to 8, additional subdominant clones were detected, accounting for 3.0 to 33.7% of the population.
V3 sequences for VF samples were obtained from time point 2, after 2 to 32 weeks
of VCV therapy (Fig. 1). Predominant clones represented 45.0 to 83.6% of the population, and subdominant clones accounted for 0.6 to 38.2% of sequences. It is notable
that V3 sequences at time point 2 were found in only a small proportion of sequences
from time point 1, if at all. In contrast, subject 7 showed signiﬁcant expansion of preexisting clones under VCV therapy. To prevent the expansion of preexisting dual-tropic
clones, patients must undergo a phenotypic assay prior to starting CCR5-antagonist
therapy. Subject 7 is a classic example of what happens when the Troﬁle assay fails to accurately capture the quasispecies tropism. The most common X4-using clone expanded from
9.0% to 83.6% following treatment. These results highlight the need for accurate and sensitive screening of tropism prior to starting CCR5-antagonist therapy. Combining both phenotypic and genotypic methods provides a better representation of a patient’s quasispecies.
The functional libraries represent those selected individual clones from each time
point that were capable of infecting U87.CD4.CCR5 or U87.CD4.CXCR4 cells at levels
signiﬁcantly above the background level. Sequences were obtained from 9 to 21
July/August 2022 Volume 10 Issue 4
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In earlier studies of subject 1, the amplicon libraries were passed through U87.CD4.CCR5
and U87.CD4.CXCR4 cell lines to select functional libraries (33). The U87 cell line is a human
glioma cell line with no signiﬁcant expression of CCR5 or CXCR4. U87 cells were stably transfected with human CD4 and human CCR5 or CXCR4 cDNAs to express high levels of each
corresponding protein (37). env sequences selected on the individual U87 cell lines from
subject 1 were characterized by next-generation sequencing (NGS), and differences were
identiﬁed for each time point (33).
In an early study of subjects 2 and 5, a portion of quasispecies was found to retain
the R5-tropic phenotype at VF. To investigate their drug resistance, individual infectious
molecular clones from amplicon libraries from each time point were isolated, sequenced,
and characterized for functional activity on U87.CD4.CCR5 and U87.CD4.CXCR4 cell lines
(33, 38). For time point 1, all molecular clones from both subjects were found to be R5tropic. At time point 2, 42% of functional clones from subject 2 and 98% of functional
clones from subject 5 were R5-tropic (38). Phylogenetic trees suggested that the V3 domain as well as the V1/V2 domains contributed to the VCV-resistant phenotype of the
R5-tropic clones. The contribution of the V1/V2 domains to drug resistance was validated
by swapping these domains between sensitive and resistant clones (38).
In the current study, of subjects 1, 3, 4, 6, 7, and 8, who demonstrated HIV shift primarily to X4-using clones after VCV treatment, we further assessed the mechanism of
VCV resistance. Functional analysis of individual clones obtained at baseline and after
development of VF and also sequence and phylogenetic analyses were employed to
identify the mechanistic basis for VF and coreceptor shift.

Microbiology Spectrum

FIG 1 V3 Sequence analyses of amplicon and functional env libraries. Amplicon libraries were generated for each of the 5 subjects at baseline and at the
time of VF. The duration of VCV therapy prior to VF is shown in each case. NGS results are shown for each amplicon library, with the number of complete

(Continued on next page)
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functional clones from baseline time point 1 and 12 to 19 functional clones from the
VF time point 2 from each of the 5 subjects (Fig. 1). Although some differences can be
seen in the proportion of each V3 sequence obtained at each time point in the functional library compared to the amplicon library, these differences were not statistically
signiﬁcant (P . 0.99).
Functional analyses of infectious molecular clones. Results of the functional analyses are shown in Fig. 2. Levels of luciferase activity varied from 103 to 107 relative light
units (RLU) among clones. It is notable that approximately half of the clones from each
time point were nonfunctional, i.e., levels of infection were not signiﬁcantly different
from background levels on both U87.CD4.CCR5 and U87.CD4.CXCR4 cell lines (data not
shown).
All baseline clones (open symbols) were R5-tropic (Fig. 2, squares), with the exception of subject 7, for whom 5 of 21 baseline clones were dual-tropic clones (Fig. 2,
circles). For VF time point 2, 33.3 to 100% of clones were dual-tropic (Fig. 2, ﬁlled
circles) and 0 to 67.3% were X4-tropic (ﬁlled triangles). X4-tropic clones were only
detected at time point 2 in subjects 4 and 8.
Genetic differences between baseline and VF clones. Phylogenetic analyses of
full-length Env and of each variable and constant region were performed to identify
genetic signatures of envelope amino acid sequence evolution. Phylogenetic trees for
the full-length envelope sequence are shown in Fig. 3A, utilizing the same symbols as
in Fig. 2. In all ﬁve subjects, sequences from before and after VCV treatment were
found on signiﬁcantly different branches, with the exception of a small number of
baseline sequences which clustered with VF sequences for subjects 6 and 7. One VF
sequence from each of subjects 6 and 7 was found to cluster with baseline sequences.
Although R5 and non-R5 sequences were on separate branches with the exception of
one sequence each from subject 6 and subject 7, X4-tropic and dual-tropic sequences
were not found on separate branches in subjects 4 and 8, the only subjects in which
X4-tropic sequences were identiﬁed.
Phylogenetic analysis of the V3 amino acid sequence showed that sequences clustered into two groups for all 5 subjects (Fig. 3B). Statistically signiﬁcant differences,
based on bootstrap assays, were detected between baseline (open symbols) and VF
sequences (closed symbols). Three outlier, preresistant clones were detected in subject
7 (S7.b.3d, S7.b.4d, S7.b.5d). Signiﬁcant clustering was also seen for V3 sequences,
based on tropism, with R5-tropic clones clustered separately from non-R5-tropic
clones. No signiﬁcant differences were seen between V3 sequences of X4 and dualtropic clones (subjects 4 and 8). Similar clustering is seen in phylogenetic trees for the
V1/V2, V4, and C3 domains (Fig. 3C to E).
V3 amino acid sequence alignments are shown in Fig. 4. The predominant baseline
clone V3 amino acid sequence is shown for each subject, and amino acid differences in
variants are indicated below for other baseline clones and those obtained from the
same subject at VF. Identical sequences are represented by dots. The V3 loop charge,
number of clones, and the experimentally determined tropism is shown for each variant. Residues 11 and 25 are boxed, since these were previously identiﬁed as key tropism determinants, a critical determinant of the Geno2pheno tropism prediction program (39). In 4 of 5 subjects (subjects 1, 4, 6, and 8), a signiﬁcant increase in V3 loop
charge was noted (P = 7.9  10229) (Fig. 4). These sequences match the consensus
clade B V3 sequence, including the GPGR V3 apex sequence found in clade B sequences rather than the GPGQ V3 apex sequence found in HIV-1 strains of other clades (40).
Although most nonfunctional clones exhibited sequences identical to those of
FIG 1 Legend (Continued)
sequences in each case indicated below the pie graph. Each slice of the pie has a unique color for a speciﬁc clone, and the percentages of clones with
identical V3 sequences are indicated. Up to 50 individual single-amplicon clones were selected for functional analysis in infection assays. The proportion of
identical V3 sequences for each of 9 to 21 functional clones for each time point are indicated, using the same color code as used for the amplicon library
pie graphs.
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FIG 2 Activity of functional envelope clones of each of the ﬁve subjects for infection of U87.CD4 cells expressing CCR5 or CXCR4. (A to E) Tropism was
determined by a single-round infection assay. Recombinant viral constructs were transfected into HEK 293T cells to produce replication-competent

(Continued on next page)
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functional clones, two baseline clones from subject 4 showed highly atypical sequences (with a Y-to-C substitution at V3 residue 21 or a GLGR V3 apex).
Expected tropism was determined by inputting the V3 sequence into Geno2pheno.
The predicted tropism of each clone was then compared with the actual tropism
obtained from the functional tests. Notably, subject 7 showed one clone with an inconsistency between the predicted and actual tropism: S7.b.4d (Fig. 4). When inputted
into Geno2pheno, this clone had a false-positive rate of 20.7% and was predicted to be
sensitive to CCR5 antagonists. In contrast, our phenotypic test found S7.b.4d to be
functionally dual-tropic. Since the functional assays were replicated and repeated with
at least two independent experiments, it is unlikely that the inconsistency was due to
experimental errors. Furthermore, individual alignments of V3 domains of Env sequences from subject 7 showed that multiple clones with the same V3 domain were R5and dual-tropic (Fig. 4). Taken together, these ﬁndings suggest that domains outside
V3 may affect tropism, and inclusion of those regions may improve the predictive accuracy of genotypic algorithms.
Phylogenetic trees for other domains of the envelope protein were also constructed
(see Fig. 3 and Fig. S1 in the supplemental material). Signiﬁcant differences were identiﬁed in the phylogenetic trees between R5 and non-R5 clones in the V1/V2, V4, and C3
domains for four of ﬁve subjects. Notably, only the V1/V2 phylogenetic analysis correctly placed S7.b.4d among the cluster of X4-using clones.
Alignments of individual V1/V2 sequences were analyzed in an attempt to identify any
common mutations or patterns. Notably, V1/V2 sequences were less diverse and more homogenous to one another following treatment (Fig. 4). These results are consistent with
our previous study (38) and suggest that the V1/V2 domains may play a role in coreceptor
switching under a CCR5 antagonist. However, further analysis of the alignments showed
no shared mutations. Sequences were also analyzed for increases or decreases in sequence
length, total charge, and N-glycosylation (41, 42). No consistent pattern was identiﬁed.
These results provide further evidence that V1/V2 mutations may be patient-speciﬁc.
Sequence alignments, based on NGS data, show the 9 positions of greatest SNP
divergence in each subject (Fig. 5). These positions map to residues within the V3, V4,
C3, and C4 domains. Positions 306 and 322 map to residues 11 and 25 in the V3 domain,
respectively. At position 398, the residue within the V4 domain of baseline sequences
was frequently replaced with a glycine in the VF sequences. At position 442 within the
C4 domain, a charged residue in baseline sequences was frequently replaced with an
uncharged residue in VF sequences. At position 355 within the C3 domain, a substitution
with an uncharged residue in VF sequences was frequently identiﬁed.
DISCUSSION
Technological advances have led to new insights into HIV-1 phylogeny (43). Singlegenome ampliﬁcation of subgenomic and full-length genomic HIV-1 sequences was
developed to preserve linkage among polymorphisms in the same viral genome copy,
to limit impact from PCR-induced misincorporation and recombination or bacterial
selection during cloning. Although most studies have used standard Sanger sequencing for
analysis, our previous study and a couple of others sequenced Illumina- or PacBio-based
pools of single-genome amplicons (33, 44–46). Recently, Paciﬁc Biosciences SMRT and
Oxford MinION Nanopore sequencing were applied for longer reads (47). The current study
utilized both single-genome Sanger sequencing analysis and Illumina NGS to characterize
HIV-1 quasispecies.
FIG 2 Legend (Continued)
virions. Viral supernatants were used to infect CCR5- and CXCR4-expressing U87.CD4 cell lines. Clones with an average luciferase readout of .2
standard deviations above the average value for negative-control wells were deﬁned as positive for coreceptor usage. RLU values were normalized
such that the cutoff was 1,000 RLU. Nonfunctional clones are not shown. RLU obtained 24 h after infection of clones obtained at baseline (open
symbols) and at VF (closed symbols) are shown in panels A to E for each subject, with squares for R5 clones, circles for dual-tropic clones, and triangles
for X4 clones. (F) Summary table of the number of functional clones of each type obtained for each subject at baseline and the time of VF. All assays
were performed at least twice.
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FIG 3 Phylogenetic trees of the full-length envelope protein (A), V3 loop (B), V1/V2 loops (C), V4 loop (D), and
C3 (E). Results of the hierarchical analysis of variants from functional libraries based on full-length amino acid

(Continued on next page)
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The current study and several prior studies suggested that X4-using HIV-1 variants
arise from preexisting minority quasispecies during CCR5 antagonist treatment (46, 48,
49). This was predicted by mathematical modeling approaches (50). Our ﬁndings highlight the importance of mutants present at frequencies of 1% or less in the development of drug resistance. This indicates the advantage of deep-sequencing technology
for genotypic studies. Subject 7 highlights the failure to identify preexisting dual-tropic
clones in the baseline quasispecies. Thus, when evaluating a patient’s eligibility for
CCR5 antagonist therapy, combining phenotypic and genotypic analyses may provide
a more accurate representation of the population tropism.
In the absence of CCR5 antagonists, a minority of individuals exhibit major HIV-1
population shifts from CCR5 to CXCR4 use (51). Depletion of memory CD41 T cells that
coexpress CCR5 and CXCR4 may select for X4-tropic strains, which could increase the
range of target cells to include naive CD41 T cells (18, 52–57). With CCR5 antagonists,
extreme and rapid HIV-1 quasispecies shifts are seen (34). In this study, we took
advantage of the selective pressure from VCV to analyze the genetic development of
coreceptor switching.
Previous studies of HIV-1 coreceptor utilization have relied on genotypic or phenotypic assays, but few investigations combined these approaches, as in the current
study. Genotypic algorithms, including Geno2Pheno, WebPSSM, PhenoSeq, SCOTH,
CoRSeqV3-C, and THETA, were developed to predict coreceptor use of clade B and
non-B HIV-1 subtypes (39, 58). However, these approaches may either underestimate
or overestimate X4 tropism, depending upon the particular assay and the context in
which it was used (59–61).
A surprising ﬁnding from the current study was the high proportion of envelope proteins with little or no detectable activity. It is unlikely that these proteins recognize alternative coreceptors without also utilizing CCR5 or CXCR4 (62). The lack of function is likely
attributed to limitations in experimental conditions rather than their Env sequence. While
some sequences did show that there were signiﬁcant deletions from the Env gene that
could have impaired the activity of the virus, most did not show amino acid sequences
that were signiﬁcantly different from their functional counterparts on the phylogenetic
trees. The lack of function may be attributed to sequence changes in the vector backbone that could have disabled the production of infectious virus. Monomeric, nonfunctional envelope proteins have been described on the surface of virions (63). These may
have arisen in some cases due to incomplete signal peptide cleavage or partial processing of the gp120/gp41 cleavage site. It is possible that nonfunctional forms of envelope
on the virion surface could account for virus capture by nonneutralizing antibodies.
A strength of our study is the longitudinal analysis of a cohort of patients. In a study
of patients failing MVC, the dominant route of escape was the emergence of X4-tropic
virus (64, 65). When MVC therapy was suspended and the virus was no longer forced
to use CXCR4, the major HIV variant in the circulation returned to a solely R5-tropic
form (48). Because selective CXCR4 antagonists are not available, there is no way to
assess the impact of speciﬁc inhibition of X4-tropic virus in vivo.
X4 tropism correlates with V3 loop charge, particularly with respect to residues 11
and 25 (66). Other compensatory mutations within other SU and TM domains mediate
coreceptor switch (55, 66–73). Our study identiﬁed several additional residues within
and outside the V3 loop that may be important for coreceptor shift. Sites 398 in V4 and
442 in C4 were previously reported to have been associated with coreceptor shift. The
398Q mutation was found to be commonly associated with end-stage R5 strains and
dual-tropic strains (74). These ﬁndings suggest that natural coreceptor shift begins
with viruses that can utilize CCR5 efﬁciently. In contrast, our studies indicate a 398G
FIG 3 Legend (Continued)
sequences are shown for each subject. Branch points with bootstrap values $95% are labeled. The symbols are
identical to those used in Fig. 2, with open symbols for baseline clones, closed symbols for those obtained at VF,
squares for R5 clones, circles for dual-tropic clones, and triangles for X4 clones. Designations for speciﬁc outlier
clones are also provided.
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FIG 4 (Continued)
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FIG 4 Sequence alignments of V3 loops (1st table) and V1/V2 loops (2nd table). Amino acid sequences are shown for R5 (R), X4 (X), dual-tropic (D), or
nonfunctional (N) clones, as well as the number of times the identical sequence was obtained, for each subject at baseline and at time of VF. Charges for the V3
loop are also shown, as are consensus V3 sequences for clades A to H HIV-1 strains and outlier clones.

mutation in only dual-tropic strains. We did not ﬁnd any common 398 mutation in
drug-resistant R5-tropic strains from the patients in our earlier study of subjects 2 and
5 (38). Our ﬁndings suggest that coreceptor shift in CCR5 antagonist-treated patients
may require a different mechanism than natural coreceptor shift. Because CCR5 antagonist therapy acts as an additional selective pressure, coreceptor shift in VCV-treated
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patients may need to occur more rapidly than coreceptor shift in untreated patients
during natural infection. The need for rapid evolution may explain why we observe the
bypass of residue 398 mutations in late-stage R5 clones and the differences in the
encoded amino acid, glutamine versus glycine.
Zhang et al. previously identiﬁed site 442 in the C4 region to be associated with
coreceptor shift but did not indicate the exact SNP (33). Our study, which supports the
previous study with a single-clone analysis, found that site 442 commonly switched
from a charged to uncharged residue. These ﬁndings suggest that combining both
deep-sequencing methods with single-clone analysis may offer a more comprehensive
genetic analysis than NGS alone.
The positions of the polymorphic residues within the envelope protein, identiﬁed
from these analyses, are shown in Fig. 6. A representation of the Env trimer (PDB ID:
4zmj) is shown in Fig. 6A with gp41, gp120, and all variable regions highlighted in colors in one of the subunits. Positions of residues identiﬁed in NGS analysis of Env are
visualized in Fig. 6B, where the sequence was obtained from subject 1 and aligned to a
previously identiﬁed HIV Env structure (PDB ID: 6B0N) to build the crystal structure
(75). Mutations featured in Fig. 6B were not included in Fig. 6A, because the sequence
was not sufﬁciently long, and therefore the positions were not highlighted. As mentioned above, position 442 resides in C4 but is shown on the crystal structure (Fig. 6B)
to be neighboring the V3 loop, while position 398 resides in V4. Position 355 is within
the C3 domain, but it is not in close proximity to any variable domain or the CD4 binding site. All three positions are located on the bottom of the Env protein (Fig. 6B), and
therefore they are likely to encounter the host cell. In addition, these mutations are all
found in regions where signiﬁcant differences were identiﬁed between baseline and
VF clones in the phylogenetic analysis. These ﬁndings taken together suggest that
these substitutions may play a role in coreceptor tropism.
Despite a signiﬁcant change occurring in the V1/V2 domains of four out of ﬁve subjects, no shared mutations were identiﬁed. This may indicate that V1/V2 mutations are
patient-speciﬁc. Due to the hypervariability of V1/V2 domains, future studies should
focus on identifying patterns rather than individual mutations. Understanding the relationship between the V3 and V1/V2 regions may allow us to better identify any potential motifs. Pastore et al. suggested that V1/V2 mutations offer a gain of function and
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FIG 5 Percent dissimilarity for speciﬁc envelope residues that differed most frequently between
baseline and VF libraries. Sites were ranked by highest average dissimilarity calculated from the ﬁve
subjects. Dissimilarity values are denoted using a color scale, with the highest percent dissimilarity
indicated as dark green and the lowest as dark red. The position of each residue, as determined by
alignment with the HXB2 sequence is shown, as well as its regional location within envelope. Sites
306 and 322 correspond to those identiﬁed by the 11/25 rule and are highlighted in blue. Other sites
with consistent changes in amino acid characteristics are highlighted in yellow. The average
percentage dissimilarity is also shown for all ﬁve subjects. The P value is indicated for the average
percent dissimilarity of that speciﬁc site among all patients compared to the average dissimilarity of
all sites among all patients. The ﬁgure also lists whether or not these speciﬁc residues were noted
previously (33, 74, 82–85).
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can compensate for the loss-of-ﬁtness V3 mutations usually required for coreceptor
switching (71).
HIV variants that use CXCR4 are less sensitive to V1/V2 and V3 loop-binding broadly
neutralizing antibodies, compared to R5-tropic strains (76). This was attributed to a protrusion in the V3 loop or interference with V3 loop exposure by the V1 loop (77). Thus, a
detailed understanding of the dynamics of envelope-coreceptor interactions should provide insights into more effective therapies and neutralizing antibodies to block HIV-1 entry.
In summary, we used phylogenetic and functional analyses with NGS and singleclone Env sequence assays of ﬁve patients who underwent VCV therapy and experienced a shift in coreceptor tropism. Phylogenetic analysis identiﬁed several regions
outside V3 that may contribute to their shift in coreceptor usage. Three amino acid
substitutions from these regions were identiﬁed from NGS and single-clone analysis.
These ﬁndings may aid in improving the accuracy of current coreceptor prediction
algorithms and further the understanding of the interaction between viral Env and
host receptors. Future directions should include site-directed mutagenesis to conﬁrm
the contribution of the mutations to coreceptor usage identiﬁed in this study.
MATERIALS AND METHODS
Patient samples. HIV-1 Env amplicons were obtained from the peripheral blood of six treatmentexperienced individuals with clade B HIV-1 who underwent a shift in coreceptor usage, from R5 tropism
to X4 or dual tropism, based on the Monogram Bioscience Troﬁle assay. Samples were collected from
two time points: baseline (week 0) and time of VF. VF was deﬁned as an HIV-1 RNA level of ,1 log10 copies/mL below the baseline level at or after 16 weeks (28).
Single-clone analysis. Patient Env plasmid libraries were generated as previously described (33, 38).
Env amplicons were cloned into a pNL4-3.Luc.DE backbone with an AfeI site. The vector and insert were
ligated using NEBuilder master mix with an insert-to-vector molar ratio of 1:1. The ligation products
were transformed into ElectroMax Stbl4-competent cells, and positive colonies were screened using the
following oligonucleotides: EnvF-ATG (59-AGAGCAGAAGACAGTGGCAAT-39) and Nef-EnvR (59-CCACTTG
CCACCCATCTTAT-39).
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FIG 6 Localization in the envelope protein of key residues inﬂuencing coreceptor utilization. A ﬁgure
derived from the X-ray crystallographic structure of envelope (PDB ID: 6B0N) is shown, along with the
positions of the residues with the highest percent dissimilarity. The positions of the V3 and V1/2
loops are also shown.
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Cell lines. HEK 293T cells were maintained in complete Dulbecco’s modiﬁed Eagle’s medium (DMEM)
with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/mL penicillin, and
1 antibacterial-antimycotic solution (100 m g/mL streptomycin and 250 ng/mL amphotericin). U87.CD4
cells were stably transfected with pBABE-CCR5-GFP or pBABE-CXCR4-GFP, constructed as previously
described (33), and maintained in DMEM supplemented with 15% fetal bovine serum, 2 mM L-glutamine,
1 mM sodium pyruvate, 1 antibacterial-antimycotic solution, 0.2 mg/mL G418, and 1 m g/mL puromycin.
Tropism assay. Tropism of recombinant viruses was determined through a single-round infection,
cell-based assay as previously described (38). Three days prior to infection, viral stocks were generated
by transfecting 3 m g of viral recombinant plasmid into 1  106 HEK 293T cells using TransIT-KT1 transfection reagent (Mirus). Viral stocks were harvested 60 h after transfection and passed through a 0.45-m m
ﬁlter. One day prior to infection, 50 m L containing 0.3  106 cells/mL (U87.CD4.CCR5 or U87.CD4.CXCR4
in 15% FBS–complete DMEM) was plated in a 96-well plate. Following 1 h of incubation with 50 m L of
16 m g/mL DEAE-dextran, the cells were inoculated in duplicate with 50 m L of untitered viral stock. After
48 h, cells were lysed with 0.2% Triton X-100 (Sigma-Aldrich, St. Louis, MO) in phosphate-buffered saline
(PBS), and luciferase activity was determined on a GloMax 96 microplate luminometer (Promega,
Madison, WI). A positive result was deﬁned as an RLU readout greater than 2 standard deviations above
the mean for mock-infected control wells. Each recombinant virus was assayed in duplicate.
Phylogenic and statistical analyses. Functional Env isolates identiﬁed by the tropism assay were
sequenced. Phylogenic analysis was conducted for the full-length Env, each variable (V1 to V5) and constant (C1 to C5) region, and gp41. Amino acid sequences were aligned using MUSCLE (78). Hierarchical
clustering analysis was performed using SeaView (79). Phylogenetic trees, apart from those for subject 8,
were constructed by using PhyML (80) with the HIV-Wm substitution model, and the reliability of
branching order was tested by bootstrap analysis using 1,000 replicates. Due to the low number of
sequences collected, subject 8 phylogenetic trees were generated using a distance-based model, BioNJ,
bootstrapped with 1,000 replicates (81). Branches with bootstrap values above 95% were considered
statistically signiﬁcant.
Next-generation sequencing. DNA samples were sequenced using the Illumina HiSeq 2000 platform, as previously described (33). For functional libraries containing full-length functionally active envelope isolates, Paciﬁc Biosciences (PacBio) RS II platform was also used to identify mutational linkages
that are more than 100 bp apart. All sequencing was performed at the McDonnell Genome Institute at
Washington University in St. Louis, MO.
For Illumina HiSeq 2000 sequencing, a minimum of 100 ng of DNA sample was processed with the
KAPA LTP library prep kit (KAPA Biosystems) to generate and amplify the dual-indexed paired-end ligation library (8 independent 50-m L reaction mixtures, 10 PCR cycles). The end products were fractionated
using the DNA 750 chip on the LabChip XT (Perkin Elmer) and puriﬁed using AMPure XP beads, and concentrations were determined using quantitative PCR according to the manufacturer’s protocol (Kapa
Biosystems). The library preparations were combined in equal molar ratios and loaded on 1 sequencing
lane (2  101 bp recipe), per the manufacturer’s recommendations (Illumina).
For PacBio RSII sequencing, 750 ng of full-length functional library envelope PCR product of approximately 3 kb in length was used for each sample, using the SMRTBell template preparation kit (Paciﬁc
Biosciences). Each sample was run on a single SMRT cell on the PacBio RSII platform (P6v2/C4 chemistry;
240-min movie length).
Crystal structures. An Env sequence from subject 1 was aligned using Phyre 2.0 (PDB ID: 6B0N) and
visualized in PyMOL (75). The ribbon structure was used for the entire sequence except for residues
identiﬁed in the NGS, where spheres were used. A surface representation of the Env trimer was generated using PDB ID: 4zmj.
Statistics. Frequencies of residues at each position were compared by one-tailed, unpaired t tests.
Data availability. The sequences identiﬁed in this study were deposited with GenBank and assigned
accession numbers OM022688 to OM022826.
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